I−Ru Chen

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Éric Rondeau, Marie Scully, Gema Ariceta et al. · Kidney International · 2020 · 219 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Association of Walking with Survival and RRT Among Patients with CKD Stages 3–5

I−Ru Chen, Su-Ming Wang, Chih‐Chia Liang et al. · Clinical Journal of the American Society of Nephrology · 2014 · 106 citations

Medicine, Physical Medicine, Exercise Prescription +12

Wavelet-based envelope features with automatic EOG artifact removal: Application to single-trial EEG data

Wei‐Yen Hsu, Chao‐Hung Lin, Hsien-Jen Hsu et al. · Expert Systems with Applications · 2011 · 67 citations

Engineering, Electrical Engineering, Neuroscience +16

Disc Height and Lumbar Index as Independent Predictors of Degenerative Spondylolisthesis in Middle-Aged Women With Low Back Pain

I−Ru Chen, Ta‐Sen Wei · Spine · 2009 · 66 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +16

Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

Thomas Barbour, Marie Scully, Gema Ariceta et al. · Kidney International Reports · 2021 · 66 citations · Full text

Life Sciences, Hematology, Pharmacotherapy +17